Klink F, Grosspietzsch R, von Klitzing L, Oberheuser F
Fortschr Med. 1979 Dec 6;97(46):2163-5.
It was evaluated by continuous cardiotocogram-, tcpO2-and EEG-registration sub partu to what extend these parameters are influenced by application of Piracetam (10 g i.v./h) to the mother. A group of 26 primigravida between 18 and 23 years of age with normal course of delivery at term was analyzed. Piracetam was applicated to 17 patients in the beginning of cervix dilatation, whereas the other patients got Laevulose as a placebo infusion. The results permit the conclusion that Piracetam provides a stabilization of cerebral functions with a certain resistence against transient hypoxia during the expulsion period. The EEG-registration demonstrates after application of Piracetam an activation of alpha-waves with simultaneous reduction of delta-waves, the CTG shows a reduced quantity of decelerations during the expulsion period. The data obtained by computerization correlate with the Apgar-Index (fetal outcome) after application of Piracetam, which was better than 9 in all cases.
通过分娩期连续胎心监护、经皮氧分压(tcpO2)和脑电图(EEG)记录来评估母亲静脉输注吡拉西坦(10 g/小时)对这些参数的影响程度。分析了一组26名年龄在18至23岁之间、足月分娩过程正常的初产妇。17例患者在宫颈扩张开始时应用吡拉西坦,而其他患者输注左旋糖作为安慰剂。结果表明,吡拉西坦可稳定脑功能,并在分娩期对短暂性缺氧具有一定的抵抗力。应用吡拉西坦后,脑电图记录显示α波激活,同时δ波减少,胎心监护显示分娩期减速次数减少。计算机处理获得的数据与应用吡拉西坦后的阿氏评分(胎儿结局)相关,所有病例的阿氏评分均优于9分。